Cooperative Agreement 2136860
Award Date
7/1/22
Completion Date
6/30/24
Dollars Obligated
$2M
Federal Agency
National Science Foundation
Awardee
Protabit, LLC (ZMG1FJD9SQ64)
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Pasadena, CA 91125, USA
Similar Awards
This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...
This $1,000,000 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports research and development efforts by Akanocure Pharmaceuticals Inc. to optimize a novel, broad-spectrum antiviral and immunomodulatory agent for oral administration against coronaviruses. The project focuses on lead optimization, including the design, synthesis, and testing of analogs with improved drug-like properties for...
This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
This $1 million cooperative agreement from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a microbial discovery and biosynthesis platform for targeted protease inhibitors to treat COVID-19. Think Bioscience, Inc. will expand its demonstrated approach using microbial systems to guide the discovery and assembly of protease inhibitors. The company will generate new intellectual property covering the discovery platform and promising small molecules...
Neyroblastgx LLC was awarded a $255,997 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The grant will support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The research is expected to be conducted between April 2021 and December 2022. The NSF Technology, Innovation, and...
This Project Grant award of $305,000.00 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program to Plexymer, Inc. in North Plainfield, NJ aims to develop an AI-driven platform to accelerate the bioformulation of antibody therapeutics. The project seeks to enable at-home self-administration of antibody medicines by pairing laboratory robotics with AI to rapidly identify stable, high-concentration formulations. This has the potential to...
Altigg Therapeutics, Inc. was awarded a $255,595 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation's Engineering program (CFDA 47.041) for the period of April 1, 2021 through March 31, 2022. Under this award, Altigg Therapeutics will develop a platform for the rapid discovery of human antibodies as therapeutics for infectious diseases such as COVID-19. The NSF Engineering program seeks to improve quality of life and economic strength through...
The National Science Foundation Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded $800,000 under the Engineering (47.041) federal grant program to develop a novel biosynthetic toolkit for rapid detection and monitoring of COVID-19 antibodies. Funded from August 1, 2022 through July 31, 2025, Indiana University will construct SARS-CoV-2 epitope peptides fused with a nanotag transducer peptide and displayed on an RNA phage platform. This biosynthetic display aims...